Exscientia PLC ADR EXAI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EXAI is a good fit for your portfolio.
News
-
Investigation into Exscientia Underway: Johnson Fistel, LLP Digs into Alleged Securities Law Violations - What Shareholders Need to Know
-
Thinking about buying stock in Praxis Precision Medicines, Safety Shot, Catalyst Pharmaceuticals, Adicet Bio, or Exscientia?
-
Exscientia Business and Financial Update for the Full Year 2023
-
Thinking about buying stock in 2Seventy Bio, Verb Technology, Exscientia, MicroCloud Hologram, or Akebia Therapeutics?
-
Exscientia to Report Full Year 2023 Financial Results on March 21, 2024
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exscientia plc - EXAI
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exscientia plc - EXAI
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exscientia plc - EXAI
Trading Information
- Previous Close Price
- $4.13
- Day Range
- $3.86–4.13
- 52-Week Range
- $3.86–9.12
- Bid/Ask
- $3.95 / $3.99
- Market Cap
- $504.24 Mil
- Volume/Avg
- 472,912 / 759,807
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 20.55
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Exscientia PLC is engaged in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of novel therapeutic compounds. The company’s technology platform combines human and computational capabilities to accelerate the process of designing novel, safe, and efficacious compounds for clinical testing in humans. The company is focused on the discovery and development of small-molecule drug candidates.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 483
- Website
- https://www.exscientia.ai
Valuation
|
Metric
|
EXAI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.32 |
Price/Sales | 20.55 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
EXAI
|
|---|---|
Quick Ratio | 6.10 |
Current Ratio | 6.22 |
Interest Coverage | −166.49 |
Quick Ratio
EXAI
Profitability
|
Metric
|
EXAI
|
|---|---|
Return on Assets (Normalized) | −21.10% |
Return on Equity (Normalized) | −32.33% |
Return on Invested Capital (Normalized) | −31.04% |
Return on Assets
EXAI
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wfxgknnlzx | Ltfg | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Hjbtclts | Vmcvrv | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jmlxmywv | Hjtmy | $97.8 Bil | |
MRNA
| Moderna Inc | Blxpfdnq | Gmy | $38.8 Bil | |
ARGX
| argenx SE ADR | Zyqsykvf | Jrjkj | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Xbthnwh | Fnlnz | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jtlbbpxz | Ngxxrl | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hzfnqyp | Cnxjlv | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ndwmwyzfwp | Pdwwv | $12.5 Bil | |
INCY
| Incyte Corp | Kzkjhkptz | Fztqqvn | $11.5 Bil |